[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO7400872A2 - Derivados sustituidos de ftalazin-1(2h)-ona - Google Patents

Derivados sustituidos de ftalazin-1(2h)-ona

Info

Publication number
CO7400872A2
CO7400872A2 CO15127891A CO15127891A CO7400872A2 CO 7400872 A2 CO7400872 A2 CO 7400872A2 CO 15127891 A CO15127891 A CO 15127891A CO 15127891 A CO15127891 A CO 15127891A CO 7400872 A2 CO7400872 A2 CO 7400872A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
new
compounds
phthalazin
substituted derivatives
Prior art date
Application number
CO15127891A
Other languages
English (en)
Inventor
Brijesh K Srivastava
Ranjit C Desai
Pankaj R Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7400872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CO7400872A2 publication Critical patent/CO7400872A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula general (I), susestereoisómeros, regioisómeros, formas tautómeras y nuevos compuestos intermediariosque intervienen en su síntesis, sus sales farmacéuticamente aceptables, solvatosfarmacéuticamente aceptables y composiciones farmacéuticas que los contienen. Lapresente invención también se refiere a un proceso de preparación de nuevos compuestosde fórmula general (I), sus estereoisómeros, regioisómeros, sus formas tautoméricas, sussales farmacéuticamente aceptables, solvatos farmacéuticamente aceptables, composicionesfarmacéuticas que los contienen, y nuevos compuestos intermediarios que intervienen en susíntesis
CO15127891A 2012-12-31 2015-06-03 Derivados sustituidos de ftalazin-1(2h)-ona CO7400872A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31

Publications (1)

Publication Number Publication Date
CO7400872A2 true CO7400872A2 (es) 2015-09-30

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15127891A CO7400872A2 (es) 2012-12-31 2015-06-03 Derivados sustituidos de ftalazin-1(2h)-ona

Country Status (30)

Country Link
US (1) US9598418B2 (es)
EP (1) EP2938598B1 (es)
JP (1) JP5930452B2 (es)
KR (1) KR101652654B1 (es)
CN (1) CN104918917A (es)
AP (1) AP2015008439A0 (es)
AR (1) AR094299A1 (es)
AU (1) AU2013368842B2 (es)
BR (1) BR112015012425A2 (es)
CA (1) CA2890309A1 (es)
CL (1) CL2015001655A1 (es)
CO (1) CO7400872A2 (es)
DK (1) DK2938598T3 (es)
EA (1) EA201591239A1 (es)
ES (1) ES2614885T3 (es)
GE (1) GEP201706691B (es)
HK (1) HK1210466A1 (es)
HR (1) HRP20170219T1 (es)
HU (1) HUE030613T2 (es)
IL (1) IL238714A0 (es)
MA (1) MA38080A1 (es)
MX (1) MX2015006780A (es)
NZ (1) NZ708255A (es)
PH (1) PH12015501199B1 (es)
PL (1) PL2938598T3 (es)
PT (1) PT2938598T (es)
SG (1) SG11201503670YA (es)
TW (1) TWI553005B (es)
WO (1) WO2014102817A1 (es)
ZA (1) ZA201503218B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
RS56776B1 (sr) 2013-11-26 2018-04-30 Hoffmann La Roche Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
WO2016187620A2 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Anti-cancer compounds
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
WO2017050792A1 (en) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6877413B2 (ja) * 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
WO2017071636A1 (zh) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017101796A1 (zh) * 2015-12-16 2017-06-22 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
BR112019019017A2 (pt) 2017-03-16 2020-04-14 Hoffmann La Roche compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP4148046A4 (en) * 2020-05-08 2024-07-24 Txinno Bioscience Inc NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITION ACTIVITY, AND USE THEREOF
WO2022192745A1 (en) * 2021-03-11 2022-09-15 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240317762A1 (en) * 2021-07-16 2024-09-26 Oregon Health & Science University Phthalazinone-based parp-1 inhibitors
CN118871432A (zh) * 2022-03-15 2024-10-29 百济神州有限公司 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EA009469B1 (ru) 2003-03-12 2007-12-28 Кудос Фармасеутикалс Лимитед Производные фталазинона
WO2005066163A2 (en) 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
US20060079510A1 (en) 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮(phthalazinone)衍生物
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HUE027641T2 (en) 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
CA2687786A1 (en) 2007-05-25 2008-12-04 Astrazenca Ab Combination of chk and parp inhibitors for the treatment of cancers
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
EP2220073B1 (en) 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ(adpリボース)ポリメラーゼ−1阻害剤としての、置換4−(4−フルオロ−3−(ピペラジン−1−カルボニル)ベンジル)フタラジン−1(2h)−オン誘導体
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US8999985B2 (en) * 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103717609B (zh) 2011-05-31 2016-05-11 江苏康缘药业股份有限公司 聚(adp-核糖)聚合酶的三环抑制剂
JP5927071B2 (ja) 2011-07-13 2016-05-25 参天製薬株式会社 Parp阻害活性を有する新規化合物
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2013097226A1 (en) 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
EA026611B1 (ru) 2012-02-09 2017-04-28 Мерк Патент Гмбх Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Also Published As

Publication number Publication date
DK2938598T3 (en) 2017-02-13
PH12015501199A1 (en) 2015-08-17
US20150291603A1 (en) 2015-10-15
AP2015008439A0 (en) 2015-05-31
IL238714A0 (en) 2015-07-01
SG11201503670YA (en) 2015-07-30
US9598418B2 (en) 2017-03-21
HUE030613T2 (en) 2017-05-29
PL2938598T3 (pl) 2017-05-31
EP2938598B1 (en) 2016-12-21
AU2013368842B2 (en) 2015-11-12
JP2016504347A (ja) 2016-02-12
HK1210466A1 (en) 2016-04-22
HRP20170219T1 (hr) 2017-04-07
MX2015006780A (es) 2015-08-06
CN104918917A (zh) 2015-09-16
PH12015501199B1 (en) 2015-08-17
AU2013368842A1 (en) 2015-05-21
CA2890309A1 (en) 2014-07-03
KR101652654B1 (ko) 2016-08-30
EP2938598A1 (en) 2015-11-04
TW201441219A (zh) 2014-11-01
ES2614885T3 (es) 2017-06-02
EA201591239A1 (ru) 2015-10-30
CL2015001655A1 (es) 2015-10-02
PT2938598T (pt) 2017-02-07
JP5930452B2 (ja) 2016-06-08
AR094299A1 (es) 2015-07-22
MA38080A1 (fr) 2018-02-28
ZA201503218B (en) 2016-01-27
TWI553005B (zh) 2016-10-11
KR20150091137A (ko) 2015-08-07
BR112015012425A2 (pt) 2017-07-11
GEP201706691B (en) 2017-06-26
NZ708255A (en) 2016-08-26
WO2014102817A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
CO7400872A2 (es) Derivados sustituidos de ftalazin-1(2h)-ona
DOP2014000016A (es) Indazoles novedosos inhibidores de janus quinasa
UY34888A (es) Inhibidores del virus de la hepatitis c
CR20140464A (es) Compuestos de heterociclilo
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
CR20110370A (es) Derivados de sulfonamida
NZ721617A (en) Heterocyclic compounds
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
MY175854A (en) Novel quinolone derivatives
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CR20110279A (es) Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
IN2014CN04530A (es)
CR20140133A (es) Compuestos de piridazinona y sus usos como inhibidores de daao
GEP20176631B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12016500885A1 (en) Novel heterocyclic compounds
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen